Francesca Levi-Schaffer

Prof. Francesca Levi-Schaffer

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in Apoptosis
Verified
Journal Article
Closed access
PDF file
Hans-Uwe SimonHans-Uwe Simon
Hans-Uwe Simon
AHA. Haj-Yehia
A. Haj-Yehia
FLFrancesca Levi-Schaffer
Francesca Levi-Schaffer

15 November 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SHSimon D Harding
Simon D Harding
JSJoanna L Sharman
Joanna L Sharman
EFElena Faccenda
Elena Faccenda
CSChris Southan
Chris Southan
APAdam J Pawson
Adam J Pawson
NINc- Iuphar
Nc- Iuphar
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, www.guidetopharmacology.org) and its precursor IUPHAR-DB, have captured expert-curated interactions between targets and ligands from selected papers in pharmacology and drug discovery since 2003. This resource continues to be developed in conjunction with the International Union of Basic and Clinical Pharmacology (IUPHAR) and the British Pharmacological Society (BPS). As previously described, our unique model of content selection and quality control is based on 96 target-class subcommittees comprising 512 scientists collaborating with in-house curators. This update describes content expansion, new features and interoperability improvements introduced in the 10 releases since August 2015. Our relationship matrix now describes ∼9000 ligands, ∼15 000 binding constants, ∼6000 papers and ∼1700 human proteins. As an important addition, we also introduce our newly funded project for the Guide to IMMUNOPHARMACOLOGY (GtoImmuPdb, www.guidetoimmunopharmacology.org). This has been ‘forked’ from the well-established GtoPdb data model and expanded into new types of data related to the immune system and inflammatory processes. This includes new ligands, targets, pathways, cell types and diseases for which we are recruiting new IUPHAR expert committees. Designed as an immunopharmacological gateway, it also has an emphasis on potential therapeutic interventions.

16 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NFNanna Fyhrquist
Nanna Fyhrquist
GMGareth Muirhead
Gareth Muirhead
SPStefanie Prast-Nielsen
Stefanie Prast-Nielsen
MJMarine Jeanmougin
Marine Jeanmougin
POPeter Olah
Peter Olah
HAHarri Alenius
Harri Alenius
Despite recent advances in understanding microbial diversity in skin homeostasis, the relevance of microbial dysbiosis in inflammatory disease is poorly understood. Here we perform a comparative analysis of skin microbial communities coupled to global patterns of cutaneous gene expression in patients with atopic dermatitis or psoriasis. The skin microbiota is analysed by 16S amplicon or whole genome sequencing and the skin transcriptome by microarrays, followed by integration of the data layers. We find that atopic dermatitis and psoriasis can be classified by distinct microbes, which differ from healthy volunteers microbiome composition. Atopic dermatitis is dominated by a single microbe (Staphylococcus aureus), and associated with a disease relevant host transcriptomic signature enriched for skin barrier function, tryptophan metabolism and immune activation. In contrast, psoriasis is characterized by co-occurring communities of microbes with weak associations with disease related gene expression. Our work provides a basis for biomarker discovery and targeted therapies in skin dysbiosis.

1 July 2003 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
GRGraham Roberts
Graham Roberts
NPNeeta Patel
Neeta Patel
FLFrancesca Levi-Schaffer
Francesca Levi-Schaffer
PHParviz Habibi
Parviz Habibi
GLGideon Lack
Gideon Lack

1 February 2002 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
EGE. Garbuzenko
E. Garbuzenko
ANA. Nagler
A. Nagler
DPD. Pickholtz
D. Pickholtz
PGP. Gillery
P. Gillery
RRR. Reich
R. Reich
FLFrancesca Levi-Schaffer
Francesca Levi-Schaffer

8 May 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
Alessandra MiceraAlessandra Micera
Alessandra Micera
EVEliana Vigneti
Eliana Vigneti
DPDalia Pickholtz
Dalia Pickholtz
RRReuven Reich
Reuven Reich
OPOrit Pappo
Orit Pappo
FLFrancesca Levi-Schaffer
Francesca Levi-Schaffer
Nerve growth factor (NGF) is a polypeptide which, in addition to its effect on nerve cells, is believed to play a role in inflammatory responses and in tissue repair. Because fibroblasts represent the main target and effector cells in these processes, to investigate whether NGF is involved in lung and skin tissue repair, we studied the effect of NGF on fibroblast migration, proliferation, collagen metabolism, modulation into myofibroblasts, and contraction of collagen gel. Both skin and lung fibroblasts were found to produce NGF and to express tyrosine kinase receptor (trkA) under basal conditions, whereas the low-affinity p75 receptor was expressed only after prolonged NGF exposure. NGF significantly induced skin and lung fibroblast migration in anin vitromodel of wounded fibroblast and skin migration in Boyden chambers. Nevertheless NGF did not influence either skin or lung fibroblast proliferation, collagen production, or metalloproteinase production or activation. In contrast, culture of both lung and skin fibroblasts with NGF modulated their phenotype into myofibroblasts. Moreover, addition of NGF to both fibroblast types embedded in collagen gel increased their contraction. Fibrotic human lung or skin tissues displayed immunoreactivity for NGF, trkA, and p75. These data show a direct pro-fibrogenic effect of NGF on skin and lung fibroblasts and therefore indicate a role for NGF in tissue repair and fibrosis.